ANL: סך החוב של החברה Adlai Nortye Ltd

Adlai Nortye Ltd. (ANL) is facing negative free cash flow due to R&D expenditures, as evidenced by current debt obligations on the GURU.Markets system chart, where 0.02 is the current value of the indicator. Risks are being mitigated through global clinical trials for advanced cancer drugs, while sales of the original drug in China support the company's liquidity.

Assessing the operational resilience of Adlai Nortye Ltd. (ANL) requires an analysis of total borrowings, which, through financial debt metrics, reflect the overall debt load and the density of borrowed capital. For this developer of anti-tumor therapies, controlling this limit is critical, as stable demand for patented molecules must ensure the servicing of obligations without risking the loss of the business's financial stability.